Pennsylvania's Pharmacy Crisis: A Law's Unfulfilled Promise
Hundreds of pharmacies are closing across Pennsylvania, leaving residents struggling to access essential medications. This crisis has sparked a heated debate about the role of corporate middlemen, known as pharmacy benefit managers (PBMs), and the effectiveness of a 2024 law aimed at addressing the issue.
But here's where it gets controversial: Despite the law's intentions, many pharmacies continue to shut down, raising questions about its implementation and enforcement.
The Law's Promise
In 2024, a bipartisan group of lawmakers passed Act 77, which aimed to support pharmacies and hold PBMs accountable for their practices. PBMs manage drug plans for employers and insurance companies, but critics argue they drive up drug costs and offer inadequate reimbursements to community pharmacies.
'Act 77 is a crucial step towards fairness,' said State Sen. Lindsey Williams, emphasizing the need for PBMs to be held accountable.
When Gov. Josh Shapiro signed the law, he criticized PBMs for their 'greed and conduct,' blaming them for independent pharmacy closures. Act 77 limits certain PBM practices and mandates transparency regarding rebates and fees.
The Reality
However, the law's impact has fallen short of expectations. Hundreds of pharmacies have closed since its enactment, including Rite Aid stores and other major chains, as well as smaller operations. This has led to longer travel distances, longer wait times, and potential gaps in patient care.
'We haven't had our blood pressure medicine in days,' patients tell Deron Shultz, CEO of Minnich's Pharmacy, who shared the struggles of his employee-owned business with lawmakers.
The Debate
PBM representatives argue that blaming them for pharmacy closures is misguided, claiming they reduce drug costs and save money for patients and the healthcare system. They point to other factors like drug company prices, online competition, and rural population declines.
'It's not just about PBMs,' said Greg Lopes, a PBM association spokesperson, suggesting a more complex web of issues.
Act 77 aimed to address several problems, including patient steering (PBMs directing patients to their own pharmacies) and clawbacks (inflated copays for PBM profit). The law also empowers the Insurance Department to study the impact of these practices on drug costs and pharmacy access.
Transparency and Enforcement
Transparency is a key focus, with Act 77 requiring annual reports on administrative fees, rebates, and reimbursement differences. The Shapiro administration believes this will expose predatory practices.
But here's the twist: Some lawmakers are concerned about the law's rollout and enforcement. They've sent detailed inquiries to the Insurance Department and the Department of Human Services, questioning the agencies' actions and the effectiveness of the law.
'We need to ensure the law is enforced as intended,' the lawmakers emphasized.
The Way Forward
The Pennsylvania Pharmacists Association has warned that further closures are likely without additional state action. Lawmakers have held hearings and sent follow-up letters, expressing concerns about the law's limitations and seeking improvements.
'Act 77 is a start, but more needs to be done,' said State Rep. Jessica Benham, the bill's prime sponsor, acknowledging the law's positive impact but calling for further legislative action.
As the situation unfolds, the fate of Pennsylvania's pharmacies and the effectiveness of Act 77 remain uncertain. Will the law live up to its promise, or will it fall short of addressing the complex challenges facing the state's pharmacies? Share your thoughts and join the discussion on this critical issue.
